The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
Open accessAbstract
Purpose: The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies. Methods: The investigation was performed in 11 laboratories across three continents and included 3,334 patients. An exploratory retrospective stage I study was designed for biomarker discovery and generated whole-genome expression profiles from 2,143 patients with leukemias and myelodysplastic syndromes. The gene expression profiling–based diagnostic accuracy was further validated in a prospective second study stage of an independent cohort of 1,191 patients. Results: On the basis of 2,096 samples, the stage I study achieved 92.2% classification accuracy for all 18 distinct classes investigated (median specificity of 99.7%). In a second cohort of 1,152 prospectively collected patients, a classification scheme reached 95.6% median sensitivity and 99.8% median specificity for 14 standard subtypes of acute leukemia (eight acute lymphoblastic leukemia and six acute myeloid leukemia classes, n = 693). In 29 (57%) of 51 discrepant cases, the microarray results had outperformed routine diagnostic methods. Conclusion: Gene expression profiling is a robust technology for the diagnosis of hematologic malignancies with high accuracy. It may complement current diagnostic algorithms and could offer a reliable platform for patients who lack access to today's state-of-the-art diagnostic work-up. Our comprehensive gene expression data set will be submitted to the public domain to foster research focusing on the molecular understanding of leukemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Nature of Statistical Learning Theory
Vapnik, V. N. (1995) · doi:10.1007/978-1-4757-2440-0 · Cited by 39,138
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917
Self-citationMLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370 · cited 2×
“C13: AML with t(11q23)/MLL C12: AML with inv(16)/t(16;16) C11: AML with t(15;17) C10: AML with t(8;21) C9: c-ALL/Pre-B-ALL without t(9;22) C8: ALL with hyperdiploid karyotype C7: ALL with t(1;19) C6: ALL with t(12;21) C5: T-ALL C4: c-ALL/Pre-B-ALL with t(9;22) C3: Pro-B-ALL with t(11q23)/MLL C2: Mature B-ALL with t(8;…”
MethodNCBI GEO: mining millions of expression profiles--database and tools
Barrett, T. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki022 · Cited by 1,206
Cited by
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationMolecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Self-citationParis, J., Morgan, M., Campos, J., Spencer, G. J., Shmakova, A., Ivanova, I., Mapperley, C., Lawson, H., Wotherspoon, D. A., Sepulveda, C., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.021 · Cited by 502
Big data privacy: a technological perspective and review
Jain, P., Gyanchandani, M., & Khare, N. (2016) · Journal of Big Data · doi:10.1186/s40537-016-0059-y · Cited by 392
A review of data mining using big data in health informatics
Herland, M., Khoshgoftaar, T. M., & Wald, R. (2014) · Journal Of Big Data · doi:10.1186/2196-1115-1-2 · Cited by 319
Rasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015) · Genes & Development · doi:10.1101/gad.260174.115 · Cited by 270
Differential regulation of myeloid leukemias by the bone marrow microenvironment
Krause, D. S., Fulzele, K., Catic, A., Sun, C. C., Dombkowski, D., Hurley, M. P., Lezeau, S., Attar, E., Wu, J. Y., Lin, H. Y., et al. (2013) · Nature Medicine · doi:10.1038/nm.3364 · Cited by 260
Bagger, F. O., Kinalis, S., & Rapin, N. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1076 · Cited by 229
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006158 · Cited by 196
Self-citationInhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Matre, P., Velez, J., Jacamo, R., Qi, Y., Su, X., Cai, T., Chan, S. M., Lodi, A., Sweeney, S. R., Ma, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12944 · Cited by 185
“0, Affymetrix) in 288 AML and 103 normal karyotype samples (donors with healthy BM and non-leukemia conditions) [13].”
BackgroundMethodResultInfluentialSelf-citationLoss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
“B, Expression of EZH2 and BCAT1 in CD34+ HSPCs or BM cells from healthy donors (normal) and patients with MDS and AML in GSE13159 (40–42) and Beat AML (43) cohorts.”
MethodInfluentialMyeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
Warnat-Herresthal, S., Perrakis, K., Taschler, B., Becker, M., Baßler, K., Beyer, M., Günther, P., Schulte-Schrepping, J., Seep, L., Klee, K., et al. (2020) · iScience · doi:10.1016/j.isci.2019.100780 · Cited by 117
Self-citationDe Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
MLL leukemia induction by genome editing of human CD34+ hematopoietic cells
Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646398 · Cited by 60
“Their transplantation in mice led to human leukemias that manifest the pathological and clinical attributes seen in MLL leukemia patients.(2-4,16) Our study highlights the application of genome-editing tools in primary human HSPCs to activate oncogenes under the control of the endogenous promoter to faithfully modelML…”
BackgroundMethodInfluentialPU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway
Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., Zheng, S., Wang, J., Zhang, L., Zhang, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.384 · Cited by 53
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
Kahl, M., Brioli, A., Bens, M., Perner, F., Kresinsky, A., Schnetzke, U., Hinze, A., Sbirkov, Y., Stengel, S., Simonetti, G., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0581-y · Cited by 48
Leukemic survival factor SALL4 contributes to defective DNA damage repair
Wang, F., Gao, C., Lu, J., Tatetsu, H., Williams, D. A., Müller, L. U., Cui, W., & Chai, L. (2016) · Oncogene · doi:10.1038/onc.2016.146 · Cited by 17
Metadata
- Authors
- Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G. T., Béné, M.-C., De Vos, J., Hernández, J. M., Hofmann, W.-K., Mills, K. I., Gilkes, A., Chiaretti, S., Shurtleff, S. A., Kipps, T. J., Rassenti, L. Z., Yeoh, A. E., Papenhausen, P. R., Liu, W.-M., Williams, P. M., & Foà, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-05-20
- Volume
- 28
- Issue
- 15
- Pages
- 2529-2537
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1994041743
- Cited by
- 654
- References
- 36
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.